Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective
- 1 April 2010
- journal article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 45 (4) , 1278-1286
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical UsePharmacological Reviews, 2006
- Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agentsPharmacology & Therapeutics, 2006
- Synthesis and biological evaluation of new tetrahydro-β-carbolines as inhibitors of the mitotic kinesin Eg5Bioorganic & Medicinal Chemistry, 2005
- New achievement and novel therapeutic applications of PDE5 inhibithors in older males.2005
- Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cellsJournal of Cellular Biochemistry, 2004
- The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1‘,2‘:1,6]pyrido[3,4-b]indole-1,4-dione AnaloguesJournal of Medicinal Chemistry, 2003
- The Discovery of Tadalafil: A Novel and Highly Selective PDE5 Inhibitor. 1: 5,6,11,11a-Tetrahydro-1H-imidazo[1‘,5‘:1,6]pyrido[3,4-b]indole-1,3(2H)-dione AnaloguesJournal of Medicinal Chemistry, 2003
- Cyclic GMP-Dependent Protein Kinase Activation and Induction by Exisulind and CP461 in Colon Tumor CellsThe Journal of Pharmacology and Experimental Therapeutics, 2001
- Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis.2001
- Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin.2000